Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 14/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 14/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397790 | 0.88 | NPC1 (0.39) | NPC1RAB9AMAPTSTAT1SMN1; SMN2 | |
| SCHEMBL17397533 | 0.87 | GUCY1A1 (0.45) | MAPTGUCY1A1GUCY1B1MEN1KMT2A | |
| SCHEMBL19107669 | 0.83 | THRB (0.47) | MAPTSMN1; SMN2GUCY1A1GUCY1B1 | |
| SCHEMBL17395670 | 0.82 | MGLL (0.40) | MAPTMGLLMEN1KMT2A | |
| SCHEMBL17395599 | 0.81 | SLC9A1 (0.38) | NPC1RAB9AMAPTSTAT1SMN1; SMN2 | |
| SCHEMBL28128282 | 0.79 | GUCY1A1 (0.33) | SMN1; SMN2GUCY1A1GUCY1B1 | |
| SCHEMBL18987084 | 0.79 | DRD2 (0.38) | NPC1RAB9AMAPTSTAT1SMN1; SMN2 | |
| SCHEMBL28128034 | 0.78 | HTT (0.39) | NPC1RAB9AMAPTSTAT1SMN1; SMN2 | |
| SCHEMBL17397635 | 0.77 | RBP4 (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL22119518 | 0.76 | ALDH1A1 (0.46) | NPC1RAB9AMAPTSTAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3164395-B1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| EP-3164395-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Novartis AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001875-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | NPC1 2359/4885RAB9A 1629/4885MAPT 2784/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | NPC1 2359/4885RAB9A 1629/4885MAPT 2784/4885 |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | NPC1 2359/4885RAB9A 1629/4885MAPT 2784/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | NPC1 2359/4885RAB9A 1629/4885MAPT 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.